Ranjit Randhawa joined Flagship Pioneering in 2021 as a senior principal working in John Mendlein’s Origination Business Unit. He has a diverse background in disease research and data science including the integration, analysis, prediction, and visualization of numerous types of data to support the development of novel bioplatforms.
Before joining Flagship, Ranjit served as the Vice President of Data Science and Analytics for Sequence Bio, where he was responsible for integrating founder population genomics with longitudinal medical records to discover indication identify targets. Previously, he was the Head of Computational Biology at Flagship-founded Axcella Therapeutics, a clinical-stage company where he built a multi-disciplinary team and conceptualized and deployed Axcella’s data science cloud infrastructure to accelerate insight generation, collaboration, and decision making.
Prior to his time in strategic development, Ranjit held roles in pharmaceutical industry developing and embracing data-led approaches in drug research. At the Novartis Institutes for BioMedical Research, he led the Computational Biology group in the neuroscience department and identified stem cell derived in-silico targets in neurodevelopmental and neuropsychiatric programs resulting in advancing programs, several publications, and a successful patent filing. At Pfizer, Ranjit developed a hypothesis generation platform, a novel approach utilized by numerous disease groups, and which advanced a cardiovascular and metabolic disease project towards the clinic.
Ranjit’s passion for data-driven scientific research led to two undergraduate degrees in Human Genetics and Computer Science from Purdue University. He earned his Ph.D. in Computer Science focusing on mathematical modeling in systems biology from Virginia Tech.